Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.4K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

9.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
9.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

327
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
327
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Scalable Synthesis of a HPK1 Inhibitor Featuring a Direct α-Arylation of Boc-Protected <i>N,N</i>-Dimethylamine by Palladium-Mediated Negishi Cross-Coupling.

The Journal of organic chemistry·2025
Same author

The Feasibility and Reliability of the Test of Gross Motor Development (TGMD-3) for Children with Disabilities in Regional Australia: A Pragmatic Pilot Study.

Physical & occupational therapy in pediatrics·2025
Same author

Key genes and immune pathways in T-cell mediated rejection post-liver transplantation identified via integrated RNA-seq and machine learning.

Scientific reports·2024
Same author

A streamlined, automated workflow to screen and triage large numbers of baculoviruses for protein expression.

Protein expression and purification·2023
Same author

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors.

ACS medicinal chemistry letters·2023
Same author

Identification, structural, and biophysical characterization of a positive modulator of human Kv3.1 channels.

Proceedings of the National Academy of Sciences of the United States of America·2023

Related Experiment Video

Updated: Nov 24, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).

Hengmiao Cheng1, Suvi T M Orr1, Simon Bailey1

  • 1La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States.

Journal of Medicinal Chemistry
|December 28, 2020
PubMed
Summary

Researchers developed a novel PI3Kα-selective inhibitor, PF-06843195, to target cancer signaling pathways. This targeted approach aims to reduce side effects compared to broader PI3K inhibitors.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Related Experiment Videos

Last Updated: Nov 24, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is crucial in human cancers.
  • PI3Kα is frequently mutated, making it a key target for cancer therapy.
  • Existing PI3K inhibitors can cause side effects due to broad class I PI3K family inhibition.

Purpose of the Study:

  • To discover a PI3Kα-selective inhibitor.
  • To minimize off-target effects and patient side effects.
  • To develop a novel therapeutic agent for PI3Kα-driven cancers.

Main Methods:

  • Structure-based drug design (SBDD).
  • Computational analysis.
  • Lead optimization and synthesis of novel compounds.

Main Results:

  • Discovery of a novel series of PI3Kα-selective inhibitors.
  • Identification of PF-06843195 (compound 1) with high PI3Kα potency.
  • Demonstration of unique selectivity for PI3K isoforms and mTOR.

Conclusions:

  • PF-06843195 represents a promising PI3Kα-selective inhibitor.
  • The developed compound offers a potential therapeutic strategy with reduced side effects.
  • Structure-based design effectively yielded a targeted cancer therapy candidate.